DRTS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Alpha Tau Medical Ltd (DRTS) is not a strong buy for a beginner, long-term investor at this time. While the company has potential with its Alpha DaRT technology, commercialization is still 2-3 years away, and the financials show no revenue and ongoing losses. The technical indicators and options data do not suggest a strong entry point, and there are no recent positive news catalysts or significant trading trends.
The MACD is negative and expanding, indicating bearish momentum. RSI is neutral at 39.394, and moving averages are converging, showing no clear trend. The stock is trading below the pivot level of 7.466, with key support at 6.587 and resistance at 8.344.
Japan's Ministry of Health, Labour and Welfare granted marketing approval for Alpha DaRT for treating unresectable locally advanced or recurrent head and neck cancer, which validates the technology and de-risks U.S. clinical development.
The company has no revenue, ongoing losses, and commercialization of its technology is still 2-3 years away. Piper Sandler downgraded the stock to Neutral, citing valuation concerns and the need for real revenue realization.
In Q3 2025, revenue remained at $0 with no growth. Net income improved to -$11.69M, up 68.78% YoY, and EPS increased to -0.14, up 40% YoY. Gross margin remains at 0%.
Mixed ratings: Piper Sandler downgraded to Neutral with a $5 price target due to valuation concerns and lack of near-term revenue. H.C. Wainwright raised the price target to $12, citing Japan's approval of Alpha DaRT as a validation of the technology.
